Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BFAST Cohort G: GDC-6036 versus docetaxel in KRAS G12C-mutant advanced or metastatic NSCLC
CTR20222238Phase 3Active
- Sponsor
- Roche
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of divarasib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Nov 2022; status: active.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222238.